Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Recaticimab (SHR-1209) in Healthy Subjects
NCT03634436Phase 1Completed
- Sponsor
- Hengrui
- Start
- Aug 2018
- Primary completion
- May 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recaticimab in hypercholesterolemia (4 cohorts), sponsored by Hengrui. Primary endpoint: Number of participants with adverse events. Started Aug 2018; status: completed.
02
Drugs
recaticimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03634436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634436.